Cost-Benefit Analysis of Stroke Rehabilitation in Iran Publisher Pubmed



Darvishi A¹ ; Mousavi M² ; Abdi Dezfouli R¹ ; Shirazikhah M³ ; Alizadeh Zarei M⁴ ; Hendi H⁵ ; Joghataei F⁵ ; Daroudi R^{6, 7} Show Affiliations
Source: Expert Review of Pharmacoeconomics and Outcomes Research Published:2023

Abstract

Background: The economic evaluation of medication interventions for stroke has been the subject of much economic research. This study aimed to examine the cost-benefit of multidisciplinary rehabilitation services for stroke survivors in Iran. Methods: This economic evaluation was conducted from the payer’s perspective with a lifetime horizon in Iran. A Markov model was designed and Quality-adjusted life years (QALYs) were the final outcomes. First, to evaluate the cost-effectiveness, the incremental cost-effectiveness ratio (ICER) was calculated. Then, using the average net monetary benefit (NMB) of rehabilitation, the average Incremental Net Monetary Benefit (INMB) per patient was calculated. The analyses were carried out separately for public and private sector tariffs. Results: While considering public tariffs, the rehabilitation strategy had lower costs (US$5320 vs. US$ 6047) and higher QALYs (2.78 vs. 2.61) compared to non-rehabilitation. Regarding the private tariffs, the rehabilitation strategy had slightly higher costs (US$6,698 vs. US$6,182) but higher QALYs (2.78 vs. 2.61) compared to no rehabilitation. The average INMB of rehabilitation vs non-rehabilitation for each patient was estimated at US$1518 and US$275 based on Public and private tariffs, respectively. Conclusion: Providing multidisciplinary rehabilitation services to stroke patients was cost-effective and has positive INMBs in public and private tariffs. © 2023 Informa UK Limited, trading as Taylor & Francis Group.